PureTech Share News (PRTC)

PureTech Information

Buy PRTC Shares
Add PRTC to Watchlist
Add PRTC to Alert

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 227.50

Bid: 226.50

Ask: 228.00

Change: 0.00 (0.00%)

Spread: 1.50 (0.662%)

Open: 0.00

High: 0.00

Low: 0.00

Prev. Close: 227.50

Last checked at -

LONDON BROKER RATINGS: Mondi and Smurfit Kappa raised, DS Smith cut

Thu, 13th Oct 2022 10:14

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

----------

FTSE 100

----------

Goldman Sachs raises Sage Group price target to 810 (760) pence - 'neutral'

----------

Barclays cuts Schroders price target to 490 (520) pence - 'equal weight'

----------

JPMorgan cuts St James's Place price target to 1,040 (1,380) pence - 'neutral'

----------

Jefferies raises London Stock Exchange target to 10,000 (9,800) pence - 'buy'

----------

JPMorgan raises London Stock Exchange target to 9,700 (9,500) pence - 'overweight'

----------

RBC starts Unite Group with 'outperform' - price target 1,025 pence

----------

Goldman Sachs cuts Vodafone price target to 160 (175) pence - 'conviction buy list'

----------

Bank of America raises Rio Tinto price target to 7,000 (6,600) pence - 'buy'

----------

Goldman Sachs raises Rio Tinto price target to 6,300 (5,700) pence - 'buy'

----------

Bank of America raises Glencore price target to 520 (480) pence - 'neutral'

----------

Goldman Sachs raises Glencore price target to 700 (610) pence - 'buy'

----------

Bank of America raises Antofagasta price target to 1,100 (1,000) pence - 'underperform'

----------

Goldman Sachs raises Antofagasta price target to 1,200 (1,160) pence - 'neutral'

----------

Morgan Stanley cuts Antofagasta price target to 1,220 (1,240) pence - 'underweight'

----------

Goldman Sachs raises Anglo American price target to 4,000 (3,700) pence - 'buy'

----------

Bank of America cuts Anglo American price target to 2,800 (2,900) pence - 'neutral'

----------

Bank of America cuts Fresnillo to 'neutral' (buy) - price target 790 (810) pence

----------

Morgan Stanley cuts DS Smith to 'equal-weight' (overweight) - price target 340 (420) pence

----------

Morgan Stanley raises Smurfit Kappa to 'overweight' (equal-weight) - price target 3,200 (4,500) pence

----------

Morgan Stanley raises Mondi to 'overweight' (equal-weight) - price target 1,800 pence

----------

Goldman Sachs cuts SSE price target to 2,048 (2,151) pence - 'buy'

----------

Goldman Sachs cuts Severn Trent price target to 2,374 (2,777) pence - 'sell'

----------

Goldman Sachs cuts United Utilities price target to 994 (1,111) pence - 'neutral'

----------

JPMorgan raises BP price target to 530 (520) pence - 'neutral'

----------

JPMorgan cuts Shell price target to 2,900 (3,000) pence - 'overweight'

----------

Goldman Sachs reinitiates Informa with 'buy' - price target 775 pence

----------

FTSE 250

----------

Bank of America raises Ferrexpo price target to 150 (140) pence - 'underperform'

----------

Bank of America cuts Centamin price target to 140 (150) pence - 'buy'

----------

Morgan Stanley cuts JD Wetherspoon target to 700 (790) pence - 'equal-weight'

----------

Goldman Sachs cuts Pennon price target to 1,016 (1,250) pence - 'neutral'

----------

Numis raises Playtech to 'buy' ('add')

----------

Berenberg cuts Tui price target to 100 (180) pence - 'sell'

----------

Bank of America cuts Asos price target to 480 (540) pence - 'underperform'

----------

Barclays cuts Marks & Spencer price target to 165 (215) pence - 'overweight'

----------

JPMorgan cuts Marks & Spencer price target to 100 (120) pence - 'neutral'

----------

Jefferies reinitiates PureTech Health with 'buy' - price target 500 pence

----------

Barclays raises Man Group price target to 290 (280) pence - 'equal weight'

----------

Barclays cuts Lancashire Holdings price target to 550 (557) pence - 'equal weight'

----------

JPMorgan raises Lancashire price target to 640 (620) pence - 'overweight'

----------

Barclays cuts Hiscox price target to 1,208 (1,212) pence - 'equal weight'

----------

JPMorgan raises Hiscox price target to 900 (880) pence - 'underweight'

----------

Barclays raises Beazley price target to 789 (780) pence - 'overweight'

----------

JPMorgan raises Beazley price target to 800 (715) pence - 'overweight'

----------

JPMorgan places Quilter on 'negative catalyst watch'

----------

JPMorgan cuts Quilter price target to 85 (110) pence - 'neutral'

----------

Barclays cuts Ashmore price target to 280 (290) pence - 'overweight'

----------

RBC cuts IntegraFin price target to 295 (330) pence - 'sector perform'

----------

SMALL CAP, AIM AND OTHER MAIN MARKET

----------

Goldman Sachs raises BHP rice target to 2,400 (2,000) pence - 'neutral'

----------

Berenberg cuts Tharisa price target to 240 (250) pence - 'buy'

----------

Bank of America cuts Hochschild Mining price target to 130 (140) pence - 'buy'

----------

Bank of America cuts Atalaya Mining price target to 250 (300) pence - 'neutral'

----------

Bank of America raises Yellow Cake price target to 640 (540) pence - 'buy'

----------

Bank of America cuts Petra Diamonds price target to 170 (180) pence - 'buy'

----------

Barclays cuts Kingspan price target to 48 (57) EUR - 'underweight'

----------

Jefferies cuts N Brown price target to 25 (30) pence - 'hold'

----------

More News

8 Aug 2022 17:06

LONDON MARKET CLOSE: Strong start to week as US inflation data looms

(Alliance News) - Stocks in London sprang into the new week after Friday's US jobs data lessened recession fears.

8 Aug 2022 16:21

IN BRIEF: PureTech shares jump on Karuna Therapeutics trial results

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Says founded entity Karuna Therapeutics reports positive phase III trial results from Emergent-2 trial for KarXT in schizophrenia. KarXT, or xanomeline-trospium, met its primary endpoint in the trial, showing a significant 9.6 point reduction in Positive and Negative Syndrome Scale total score compared to a placebo. The PANSS scale measures the symptom severity of patients with schizophrenia. The trial also met key secondary endpoints, the firm says. Karuna plans to submit a new drug application with the US Food & Drug Administration in mid-2023.

1 Aug 2022 21:21

IN BRIEF: PureTech Health's Aliki starts phase three study for SDT-001

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Notes that founded entity Akili Interactive Labs Inc has start a pivotal phase three randomised, controlled study of SDT-001, a candidate designed to improve the measures of attention in children diagnosed with ADHD.

11 Jul 2022 19:15

TRADING UPDATES: BlueRock hit by extreme weather; Harbour drills well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

30 Jun 2022 21:50

IN BRIEF: PureTech Health begins pulmonary fibrosis study

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Begins late-stage clinical study of its wholly-owned candidate LYT-100, or deupirfenidone, in idiopathic pulmonary fibrosis. Will evaluate efficacy of two doses, as well as relative tolerability and efficacy with pirfenidone. IPF is a chronic condition causing progressive scarring of the lungs, which currently has a poor prognosis. Also advances LYT-200 programme through clinical development, and plans to begin leukemia study by the end of 2022.

28 Jun 2022 14:45

IN BRIEF: PureTech Health's founded firm Vedanta launches new facility

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Announces that its founded firm Entity Vedanta Biosciences Inc launches a new manufacturing facility. The facility will "provide clinical and commercial supply of oral therapies" for people infected with a diarrhoea-causing bacteria, firm says.

21 Jun 2022 14:24

IN BRIEF: PureTech Health's Gelesis wins USD15 million Plenity order

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Investee Gelesis Holdings Inc receives another USD15 million pre-order for its weight management aid product Plenity from its distribution partner, New-York based telehealth firm Ro. It brings the total orders from Ro to USD55 million, out of which USD45 million was ordered in the last 12 months, PureTech Health adds.

14 Jun 2022 16:54

IN BRIEF: PureTech achieves availability milestone for LYT-300 study

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Announces results from phase two study of LYT-100-COV on patients with post acute or long Covid with respiratory complications.

14 Jun 2022 07:33

PureTech reports 'Glyph' milestone, disappointing long Covid results

(Sharecast News) - PureTech Health said on Tuesday that it had met a milestone in proving its 'Glyph' therapeutic platform, while separately announcing disappointing results from a study into long Covid.

1 Jun 2022 18:21

TOP NEWS: Centrica warms up for FTSE 100 as Royal Mail sent packing

(Alliance News) - FTSE Russell confirmed on Wednesday that the following changes will take effect to its UK indices from the market open on Monday, June 20 after completing its quarterly review.

25 May 2022 10:18

Centrica and Johnson Matthey indicated to join FTSE 100, Asos in 250

(Alliance News) - British Gas-owner Centrica PLC and chemical firm Johnson Matthey PLC are set to return to the FTSE 100 index next month, replacing television broadcaster ITV PLC and postal operator Royal Mail PLC, according to indicative changes released by FTSE Russell on Tuesday.

5 May 2022 12:11

LONDON MARKET MIDDAY: Pound slips as BoE opts for quarter-point hike

(Alliance News) - Stock prices in London were higher, while the pound was flat, on Thursday, after the Bank of England as expected raised UK interest rates by a quarter percentage point.

5 May 2022 11:18

IN BRIEF: PureTech shares rise as unveils USD50 million share buyback

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Approves share buyback of up to USD50 million. Programme follows "follows consultation with shareholders and is consistent with PureTech's capital allocation strategy and stated approach to drive additional value for its shareholders," company says. PureTech says it had USD413.2 million of net cash and cash equivalents at March 31. Given size of balance sheet, PureTech is confident it can return capital to shareholders and also maintain "sufficient cash on hand to deliver" on strategic priorities.

5 May 2022 10:09

PureTech to buy back up to $50m of shares

(Sharecast News) - PureTech Health has announced a $50m share buyback programme, sending shares in the FTSE 250 biotech sharply higher.

4 May 2022 13:35

PureTech entity Gelesis reports positive data for weight loss drug

(Alliance News) - Boston-based biotechnology company PureTech Health PLC's founded entity Gelesis Holdings Inc said on Wednesday that its weight loss drug showed positive responses in adults in clinical trials.

Latest Share Chat

PureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: Mondi and Smurfit Kappa raised, DS Smith cut

Login to your account

Quickpicks are a member only feature

Login to your account